Show simple item record

dc.contributor.authorRogers, Andy
dc.contributor.authorAkram, Perways
dc.contributor.authorRavenscroft, Jane C
dc.date.accessioned2022-10-18T15:52:42Z
dc.date.available2022-10-18T15:52:42Z
dc.date.issued2022
dc.identifier.citationLeighton, P., Chalmers, J.R., Batchelor, J.M., Rogers, A., Akram, P., Haines, R.H., Meakin, G.D., White, J., Ravenscroft, J.C., Sach, T.H., Santer, M., Whitton, M.E., Eleftheriadou, V. and Thomas, K.S. (2022) 'Prescribing and using vitiligo treatments: lessons from a nested process evaluation within the HI-Light vitiligo randomized controlled trial', Clinical and experimental dermatology, 47(8), pp. 1480-1489. doi: https://dx.doi.org/10.1111/ced.15193en_US
dc.identifier.issn1365-2230
dc.identifier.urihttp://hdl.handle.net/20.500.12904/15833
dc.description.abstractBACKGROUND: The HI-Light Trial demonstrated that for active, limited vitiligo, combination treatment with potent topical corticosteroid (TCS) and handheld narrowband ultraviolet B offers a better treatment response than potent TCS alone. However, it is unclear how to implement these findings., AIM: We sought to answer three questions: (i) Can combination treatment be used safely and effectively by people with vitiligo?; (ii) Should combination treatment be made available as routine clinical care?; and (iii) Can combination treatment be integrated within current healthcare provision?, METHODS: This was a mixed-methods process evaluation, including semi-structured interviews with a purposive sample of trial participants, structured interviews with commissioners, and an online survey and focus groups with trial staff. Transcripts were coded by framework analysis, with thematic development by multiple researchers., RESULTS: Participants found individual treatments easy to use, but the combination treatment was complicated and required nurse support. Both participants and site investigators felt that combination treatment should be made available, although commissioners were less certain. There was support for the development of services offering combination treatment, although this might not be prioritized above treatment for other conditions. A 'mixed economy' model was suggested, involving patients purchasing their own devices, although concerns regarding the safe use of treatments mean that training, monitoring and ongoing support are essential. The need for medical physics support may mean that a regional service is more practical., CONCLUSION: Combination treatment should be made available for people seeking treatment for vitiligo, but services require partnership with medical physics and ongoing training and support for patients. Copyright © 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
dc.description.urihttps://dx.doi.org/10.1111/ced.15193en_US
dc.language.isoenen_US
dc.publisherJohn Wiley and Sons Ltden_US
dc.subjectDermatologic agentsen_US
dc.subjectUltraviolet therapyen_US
dc.subjectVitiligoen_US
dc.titlePrescribing and using vitiligo treatments: lessons from a nested process evaluation within the HI-Light vitiligo randomized controlled trialen_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1111/ced.15193en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.dateFCD2022-10-18T15:52:43Z
refterms.versionFCDVoR
refterms.dateFOA2022-10-18T15:52:43Z
refterms.panelUnspecifieden_US
refterms.dateFirstOnline2022
html.description.abstractBACKGROUND: The HI-Light Trial demonstrated that for active, limited vitiligo, combination treatment with potent topical corticosteroid (TCS) and handheld narrowband ultraviolet B offers a better treatment response than potent TCS alone. However, it is unclear how to implement these findings., AIM: We sought to answer three questions: (i) Can combination treatment be used safely and effectively by people with vitiligo?; (ii) Should combination treatment be made available as routine clinical care?; and (iii) Can combination treatment be integrated within current healthcare provision?, METHODS: This was a mixed-methods process evaluation, including semi-structured interviews with a purposive sample of trial participants, structured interviews with commissioners, and an online survey and focus groups with trial staff. Transcripts were coded by framework analysis, with thematic development by multiple researchers., RESULTS: Participants found individual treatments easy to use, but the combination treatment was complicated and required nurse support. Both participants and site investigators felt that combination treatment should be made available, although commissioners were less certain. There was support for the development of services offering combination treatment, although this might not be prioritized above treatment for other conditions. A 'mixed economy' model was suggested, involving patients purchasing their own devices, although concerns regarding the safe use of treatments mean that training, monitoring and ongoing support are essential. The need for medical physics support may mean that a regional service is more practical., CONCLUSION: Combination treatment should be made available for people seeking treatment for vitiligo, but services require partnership with medical physics and ongoing training and support for patients. Copyright © 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


Files in this item

Thumbnail
Name:
Prescribing and using vitiligo ...
Size:
576.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record